[Clinical significance of respiratory infections associated with lung cancer patients].

Akira Watanabe(Tohoku University), Nobuyuki Matsubara(Tohoku University), Toshiaki Kikuchi(Tohoku University), Shunichi Sugawara(Sendai Kousei Hospital), Yoshihiro Honda, Yuka Numata(Chugoku Rosai Hospital), Yushi Nakai(Tohoku University), Yutaka Tokue(Tohoku University), Joji Sato(Tohoku University), Junichi Saito
PubMed
July 1, 1992
Cited by 6

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642